Methicillin-resistant Staphylococcus aureus: A community health threat

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 16-23

  Cataldo, Maria Adriana ^a   Taglietti, Fabrizio ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antimicrobials; CA MRSA; Drug resistance; Methicillin resistant Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MINOCYCLINE; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGRANULOCYTOSIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; APLASTIC ANEMIA; ARTICLE; BLOOD DYSCRASIA; CLINICAL FEATURE; COMMUNITY ACQUIRED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; COMMUNITY ACQUIRED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; DISEASE SURVEILLANCE; DRUG FATALITY; DRUG POTENTIATION; HUMAN; LACTIC ACIDOSIS; LIVER NECROSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; NONHUMAN; PUBLIC HEALTH; RISK FACTOR; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; DRUG EFFECT; FEMALE; HOSPITALIZATION; INCIDENCE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PROGNOSIS; REVIEW; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; MALE; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS;

EID: 79952198811     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2218     Document Type: Article

References (74)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520-532.
2. Pujol M, Peña C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med. 1996;100(5):509-516.
3. Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med. 1982;96(1):11-16.
4. Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerging Infect Dis. 2005;11(6):928-930.
5. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40(12):1785-1791.
6. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45(3):311-320.
7. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004;139(9):947-951.
8. Minnesota Department of Health. Minnesota Department of Health Disease Control Newsletter. Community-associated methicillin-resistant Staphylococcus aureus in Minnesota. 2004;32:61-72.
9. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(5):1323-1336.
10. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976-2984.
11. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007;13(2):236-242.
12. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41(11):5113-5120.
13. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA. 1999;282(12):1123-1125.
14. Kennedy AD, Otto M, Braughton KR, et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci U S A. 2008;105(4):1327-1332.
15. Wang CC, Lo WT, Chu ML, Siu LK. Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus isolates from children in Taiwan. Clin Infect Dis. 2004;39(4):481-487.
16. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40(11):4289-4294.
17. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis. 2002;35(7):819-824.
18. Witte W, Braulke C, Cuny C, et al. Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis. 2005;24(1):1-5.
19. Witte W, Cuny C, Strommenger B, et al. Emergence of a new community acquired MRSA strain in Germany. Euro Surveill. 2004;9(1):16-18.
20. Robinson DA, Kearns AM, Holmes A, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet. 2005;365:1256-1258.
21. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;41(suppl 4):S269-S272.
22. Eguia JM, Chambers HF. Community-acquired methicillin-resistant Staphylococcus aureus: epidemiology and potential virulence factors. Curr Infect Dis Rep. 2003;5(6):459-466.
23. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005;40(4):562-573.
24. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352(5):468-475.
25. Methicillin-resistant Staphylococcus aureus infection among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mort Wkly Rep. 2003;52(33):793-795.
26. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(5):752-760.
27. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles county, California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2003;52:88.
28. Zinderman CE, Conner B, Malakooti MA, et al. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerging Infect Dis. 2004;10(5):941-944.
29. Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis. 2010;50(7):979-987.
30. Allen JE. Skin infection spreads among gay men in L.A. Los Angeles, CA: Los Angeles Times; 2003.
31. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA. 2001;286(10):1201-1205.
32. Maguire GP, Arthur AD, Boustead PJ, Dwyer B, Currie BJ. Clinical experience and outcomes of community-acquired and nosocomial methicillin-resistant Staphylococcus aureus in a northern Australian hospital. J Hosp Infect. 1998;38(4):273-281.
33. Adam H, McGeer A, Simor A. Fatal case of post-influenza, community-associated MRSA pneumonia in an Ontario teenager with subsequent familial transmission. Can Commun Dis Rep. 2007;33(4):45-48.
34. Adcock PM, Pastor P, Medley F, et al. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis. 1998;178(2):577-580.
35. Ragan P. Community-acquired MRSA infection: an update. JAAPA. 2006;19(4):24-29.
36. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S aureus infection: a prospective investigation. Clin Infect Dis. 2007;44(4):471-482.
37. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. EMERGEncy ID Net Study Group. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
38. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436-1444.
39. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445-1453.
40. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45:311-20
41. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259-270.
42. Lee TC, Carrick MM, Scott BG, et al. Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital. Am J Surg. 2007;194(6):809-812.
43. Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop. 2006;26(6):703-708.
44. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004;23(8):701-706.
45. Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics. 2006;117(2):433-440.
46. Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med. 2003;29(10):1840-1843.
47. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894-899.
48. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.
49. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-107.
50. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics. 2005;115(3):642-648.
51. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353(12):1245-1251.
52. Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis. 2005;40(7):941-947.
53. Struelens MJ, Hawkey PM, French GL, Witte W, Tacconelli E. Laboratory tools and strategies for methicillin-resistant Staphylococcus aureus screening, surveillance and typing: state of the art and unmet needs. Clin Microbiol Infect. 2009;15(2):112-129.
54. Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008;46(11):1637-1646.
55. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117(5):390-398.
56. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007;51(2):423-428.
57. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(7):2628-2630.
58. Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med. 2006;119(11):943-951.
59. Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22(7):593-598.
60. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40(2):280-285.
61. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital-and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2006;193(11):1495-1503.
62. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007;45(4):1350-1352.
63. Nathwani D, Morgan M, Masterton RG, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976-994.
64. Howden BP, Grayson ML. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006;42(3):394-400.
65. Preventing the Spread of Vancomycin Resistance-A Report from the Hospital Infection Control Practices Advisory Committee prepared by the Subcommittee on Prevention and Control of Antimicrobial-Resistant Microorganisms in Hospitals; comment period and public meeting-CDC. Notice. Fed Regist. 1994;59(94):25758-25763.
66. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26(6):876-879.
67. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J. 2005;35(suppl 2):S136-S140.
68. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996;37(2):209-222.
69. Sato M, Chida K, Suda T, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother. 2006;12(4):185-189.
70. Harding I, Macgowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000;45(6):835-841.
71. Yanagihara K, Kihara R, Araki N, et al. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive methicillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection. Int J Antimicrob Agents. 2009;34(5):477-481.
72. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006;7(10):1381-1397.
73. Marty FM, Yeh WW, Wennersten CB. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44(2):595-597.
74. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007;195(2):202-211.